Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology firm focused on serious degenerative genetic diseases, announced that CEO João Siffert will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 8:30 a.m. ET in New York City. A live webcast will be available on their investor website, archived for 30 days post-presentation. The company is known for its GeneTAC™ technology aimed at targeting genes responsible for diseases like Friedreich ataxia and myotonic dystrophy type-1.

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 8:30 a.m. ET in New York City.

A live webcast will be available in the investor section of the company’s website at www.designtx.com. The webcast will be archived for 30 days following the presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Contact:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

When is Design Therapeutics' presentation at the Jefferies Healthcare Conference?

Design Therapeutics will present on June 8, 2022, at 8:30 a.m. ET.

Where can I watch the Design Therapeutics presentation?

The presentation will be available via a live webcast on the investor section of their website.

What is the focus of Design Therapeutics' research?

Design Therapeutics focuses on developing therapies for serious degenerative genetic diseases using GeneTAC™ technology.

What diseases is Design Therapeutics targeting with its GeneTAC™ technology?

They are targeting diseases like Friedreich ataxia and myotonic dystrophy type-1.

How long will the webcast of the Design Therapeutics presentation be available?

The webcast will be archived for 30 days after the presentation.